These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23168929)

  • 1. Assessing and treating hepatic encephalopathy in the older patient.
    Stephens S; Nyman H; Shane-McWhorter L
    Consult Pharm; 2012 Nov; 27(11):797-802. PubMed ID: 23168929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered mental status in cirrhosis: etiologies and outcomes.
    Rahimi RS; Elliott AC; Rockey DC
    J Investig Med; 2013 Apr; 61(4):695-700. PubMed ID: 23474970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
    Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
    Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting compliance and persistence with treatment for hepatic encephalopathy.
    Neff G
    Pharmacotherapy; 2010 May; 30(5 Pt 2):22S-7S. PubMed ID: 20412037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment guidelines for hepatic encephalopathy.
    Thompson JR
    Pharmacotherapy; 2010 May; 30(5 Pt 2):4S-9S. PubMed ID: 20412034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain tryptophan perturbation in hepatic encephalopathy: implications for effects by neuropsychoactive drugs in clinical practice.
    Bengtsson F; Bergqvist PB; Apelqvist G
    Adv Exp Med Biol; 1997; 420():1-33. PubMed ID: 9286423
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
    Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
    Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment and usefulness of clinical scales for semiquantification of overt hepatic encephalopathy.
    Sakamoto M; Perry W; Hilsabeck RC; Barakat F; Hassanein T
    Clin Liver Dis; 2012 Feb; 16(1):27-42. PubMed ID: 22321463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropsychiatric condition must be thoroughly assessed before treatment of hepatic encephalopathy.
    Lewis MB
    BMJ; 1999 Aug; 319(7207):455. PubMed ID: 10445943
    [No Abstract]   [Full Text] [Related]  

  • 10. Minimal hepatic encephalopathy: time to recognise and treat.
    Dhiman RK; Chawla YK
    Trop Gastroenterol; 2008; 29(1):6-12. PubMed ID: 18564660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paroxystic neuropsychological symptoms as the early expression of hepatic encephalopathy. A case report.
    Abts H; Crols R; Mariën P; Saerens J; Holvoet J; de Deyn P
    Acta Neurol (Napoli); 1993 Aug; 15(4):268-76. PubMed ID: 8249670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options for hepatic encephalopathy.
    Schiano TD
    Pharmacotherapy; 2010 May; 30(5 Pt 2):16S-21S. PubMed ID: 20412036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomics of hepatic encephalopathy.
    Neff G
    Pharmacotherapy; 2010 May; 30(5 Pt 2):28S-32S. PubMed ID: 20412038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The imminent peril in the law of July the fifth 2011, two years later: the impact on health?].
    Mondoloni A; Buard M; Nargeot J; Vacheron MN
    Encephale; 2014 Dec; 40(6):468-73. PubMed ID: 24703930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of the initial diagnosis among patients with an acutely altered mental status.
    Sporer KA; Solares M; Durant EJ; Wang W; Wu AH; Rodriguez RM
    Emerg Med J; 2013 Mar; 30(3):243-6. PubMed ID: 22362650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Follow-up discussion on restructuring the medical-service system].
    Kato S; Kamada A
    Kekkaku; 2012 Dec; 87(12):809-19. PubMed ID: 23350522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered consciousness in Ugandan hospital admissions.
    Rwebembera J; Wilson T
    Trop Doct; 2009 Oct; 39(4):240-1. PubMed ID: 19762582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].
    Abdo-Francis JM; Pérez-Hernández JL; Hinojosa-Ruiz A; Hernández-Vásquez JR
    Rev Gastroenterol Mex; 2010; 75(2):135-41. PubMed ID: 20615780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of cognitive impairment in cirrhotic patients with bacterial infections.
    Merli M; Lucidi C; Pentassuglio I; Giannelli V; Giusto M; Di Gregorio V; Pasquale C; Nardelli S; Lattanzi B; Venditti M; Riggio O
    J Hepatol; 2013 Aug; 59(2):243-50. PubMed ID: 23523580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin for the treatment of hepatic encephalopathy.
    Mantry PS; Munsaf S
    Transplant Proc; 2010 Dec; 42(10):4543-7. PubMed ID: 21168733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.